NATCO Pharma Reports Strong Q3 FY2025 Results

NATCO Pharma Limited announced robust financial results for the third quarter of FY2025. The company's consolidated revenue from operations reached 4.75 billion rupees, while consolidated net profit stood at 1.33 billion rupees. The company also declared an interim dividend of ₹3.50 per equity share. This performance demonstrates significant growth compared to the previous year, driven by strong exports in the formulation business and a stable domestic pharmaceutical market. The company's board has declared a second interim dividend of 1.5 rupees per equity share. NATCO Pharma's continued success in both domestic and international markets underscores its strategic focus on affordable medicines and market leadership.
Source: NATCO Pharma Limited Regulatory Filing